Trial results will tell the full story. Well actually only half the story because it’s an open-label trial, that is not randomised and not blind.
I like your optimism but to say that the trial must be going great guns because it’s still going is a stretch.
The usual suspects were saying the exact same thing about DEP-Docetaxel for 5 long years after it was originally due to finish in 2018. Look how that turned out.
Same theme for DEP-Cabazitaxel.
Yet here we are at 13 cents. The market has spoken.
Ann: Half Yearly Report and Accounts, page-3
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
